293 related articles for article (PubMed ID: 11313934)
1. Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A.
Rashid SF; Moore JS; Walker E; Driver PM; Engel J; Edwards CE; Brown G; Uskokovic MR; Campbell MJ
Oncogene; 2001 Apr; 20(15):1860-72. PubMed ID: 11313934
[TBL] [Abstract][Full Text] [Related]
2. Antiproliferative signalling by 1,25(OH)2D3 in prostate and breast cancer is suppressed by a mechanism involving histone deacetylation.
Banwell CM; Singh R; Stewart PM; Uskokovic MR; Campbell MJ
Recent Results Cancer Res; 2003; 164():83-98. PubMed ID: 12899515
[TBL] [Abstract][Full Text] [Related]
3. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
[TBL] [Abstract][Full Text] [Related]
4. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation.
Zhuang SH; Burnstein KL
Endocrinology; 1998 Mar; 139(3):1197-207. PubMed ID: 9492054
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitors suppress telomerase reverse transcriptase mRNA expression in prostate cancer cells.
Suenaga M; Soda H; Oka M; Yamaguchi A; Nakatomi K; Shiozawa K; Kawabata S; Kasai T; Yamada Y; Kamihira S; Tei C; Kohno S
Int J Cancer; 2002 Feb; 97(5):621-5. PubMed ID: 11807787
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells.
Rokhlin OW; Glover RB; Guseva NV; Taghiyev AF; Kohlgraf KG; Cohen MB
Mol Cancer Res; 2006 Feb; 4(2):113-23. PubMed ID: 16513842
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects.
Campbell MJ; Reddy GS; Koeffler HP
J Cell Biochem; 1997 Sep; 66(3):413-25. PubMed ID: 9257197
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells.
Frønsdal K; Saatcioglu F
Prostate; 2005 Feb; 62(3):299-306. PubMed ID: 15389787
[TBL] [Abstract][Full Text] [Related]
10. Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity.
Ly LH; Zhao XY; Holloway L; Feldman D
Endocrinology; 1999 May; 140(5):2071-6. PubMed ID: 10218956
[TBL] [Abstract][Full Text] [Related]
11. Altered nuclear receptor corepressor expression attenuates vitamin D receptor signaling in breast cancer cells.
Banwell CM; MacCartney DP; Guy M; Miles AE; Uskokovic MR; Mansi J; Stewart PM; O'Neill LP; Turner BM; Colston KW; Campbell MJ
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2004-13. PubMed ID: 16609009
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin.
Campbell MJ; Elstner E; Holden S; Uskokovic M; Koeffler HP
J Mol Endocrinol; 1997 Aug; 19(1):15-27. PubMed ID: 9278857
[TBL] [Abstract][Full Text] [Related]
13. Synergistic inhibition of prostate cancer cell lines by a 19-nor hexafluoride vitamin D3 analogue and anti-activator protein 1 retinoid.
Campbell MJ; Park S; Uskokovic MR; Dawson MI; Jong L; Koeffler HP
Br J Cancer; 1999 Jan; 79(1):101-7. PubMed ID: 10408700
[TBL] [Abstract][Full Text] [Related]
14. A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.
Patra N; De U; Kim TH; Lee YJ; Ahn MY; Kim ND; Yoon JH; Choi WS; Moon HR; Lee BM; Kim HS
Biomed Pharmacother; 2013 Jun; 67(5):407-15. PubMed ID: 23583193
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells.
Yee SW; Campbell MJ; Simons C
J Steroid Biochem Mol Biol; 2006 Mar; 98(4-5):228-35. PubMed ID: 16483768
[TBL] [Abstract][Full Text] [Related]
16. Distinct HDACs regulate the transcriptional response of human cyclin-dependent kinase inhibitor genes to Trichostatin A and 1alpha,25-dihydroxyvitamin D3.
Malinen M; Saramäki A; Ropponen A; Degenhardt T; Väisänen S; Carlberg C
Nucleic Acids Res; 2008 Jan; 36(1):121-32. PubMed ID: 17999998
[TBL] [Abstract][Full Text] [Related]
17. Carboxypeptidase A3 (CPA3): a novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells.
Huang H; Reed CP; Zhang JS; Shridhar V; Wang L; Smith DI
Cancer Res; 1999 Jun; 59(12):2981-8. PubMed ID: 10383164
[TBL] [Abstract][Full Text] [Related]
18. Effects of potent vitamin D3 analogs on clonal proliferation of human prostate cancer cell lines.
de Vos S; Holden S; Heber D; Elstner E; Binderup L; Uskokovic M; Rude B; Chen DL; Le J; Cho SK; Koeffler HP
Prostate; 1997 May; 31(2):77-83. PubMed ID: 9140119
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells.
Swamy N; Chen TC; Peleg S; Dhawan P; Christakos S; Stewart LV; Weigel NL; Mehta RG; Holick MF; Ray R
Clin Cancer Res; 2004 Dec; 10(23):8018-27. PubMed ID: 15585637
[TBL] [Abstract][Full Text] [Related]
20. DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines.
Walton TJ; Li G; Seth R; McArdle SE; Bishop MC; Rees RC
Prostate; 2008 Feb; 68(2):210-22. PubMed ID: 18092350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
